<DOC>
	<DOCNO>NCT01557712</DOCNO>
	<brief_summary>The objective study evaluate effectiveness ketamine ( infusion 0.5mg/kg ) venlafaxine compare use venlafaxine alone treatment major depression ( MADRS score ≥ 20 ) six week treatment .</brief_summary>
	<brief_title>Estimate Efficiency Association Injection Ketamine Venlafaxine Severe Major Depressive Disorder Six Weeks</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Patients age 18 , Introducing single depressive episode recurrent unipolar Responding diagnosis severe major depressive episode accord DSM IV ( Diagnostic Statistical Manual Mental Disorders Fourth Edition ) : MADRS score ≥ 20 , absence treatment ketamine analgesia anesthesia last 6 month Affiliate ( beneficiary ) social security system Informed consent sign Contraindication ketamine administration treatment venlafaxine ; Failure treatment venlafaxine current episode ( low 150 mg 15 day ) ; Axis I diagnosis accord DSM IV bipolar disorder ( type I , II III ) , schizoaffective disorder , schizophrenia , alcohol toxic wean least 6 month ; Current Episode resistant stage V accord classification Thase Rush ( fail course bilateral ECT ) ; Major depressive episode severity criterion ( significant risk suicide MADRS score ≥ 5SI ; decubitus complication , intravenous hydration ) ; episode currently treat fluoxetine ; Patients hospitalize without consent measure legal protection ( guardianship , curatorship ) ; Affection Organic likely affect cognitive ability brain structure ( eg , HIV , MS , lupus , Parkinson 's disease , epilepsy , dementia ... ) decompensation ; Pregnancy breastfeed underway .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>